MarketLens

Log in
Stock AnalysisPro

What's Behind the Recent Insider Selling at NewAmsterdam Pharma (NAMS)

4 months ago
SHARE THIS ON:

What's Behind the Recent Insider Selling at NewAmsterdam Pharma (NAMS)

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

What's Behind the Recent Insider Selling at AnaptysBio

What's Behind the Recent Insider Selling at AnaptysBio

3 months ago
What's Behind the Recent Insider Selling at Vicor

What's Behind the Recent Insider Selling at Vicor

2 months ago
What's Behind the Recent Insider Selling at International Seaways

What's Behind the Recent Insider Selling at International Seaways

4 months ago
What's Behind the Recent Insider Selling at GigaCloud Technology

What's Behind the Recent Insider Selling at GigaCloud Technology

4 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCryptoNew Release

You may also like

Stock News•1 months ago

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?

Parabilis Medicines (PBLS) director Alan Sebulsky bought $474K in stock at ~$27.06/share, raising his stake to 30,000 shares. The insider purchase signals confidence shortly after the IPO.
PBLS
Stock News•1 months ago

Insiders Are Selling These 3 Stocks—Should Investors Be Concerned?

Insider sales are rising across three stocks—two large-caps in industrials and retail, plus a small-cap chip stock—signaling bearish sentiment, though severity varies by name.
GEV
Stock News•1 months ago

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

Nan Fung Group sold $4.3M in Oculis shares after the lead drug stumbled, signaling insider concern over the clinical-stage biotech's late-stage topical therapies for diabetic and neuro-ophthalmic eye ...
OCS
Stock News•2 months ago

NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript

NewAmsterdam Pharma (NAMS) provided a clinical development update regarding its ongoing PREVAIL trial. The company outlined specific plans for an interim analysis, which will serve as a key milestone ...
NAMS

Breaking News

View All →
Earnings
Regional Banks
Earnings Surprise
Biotech & Pharma
Corporate Earnings
Debt/Share Issuance
Financials
Free Cash Flow (FCF)
M&A
Radiopharmaceuticals

Featured Articles

LXP Industrial Trust: A $5.2 Billion Acquisition Validates the Pure-Play Industrial REIT Strategy

LXP Industrial Trust: A $5.2 Billion Acquisition Validates the Pure-Play Industrial REIT Strategy

5 hours ago
Prologis's High-Stakes Bid for SEGRO: A Deadline Looms for European Logistics Dominance

Prologis's High-Stakes Bid for SEGRO: A Deadline Looms for European Logistics Dominance

5 hours ago
Kinder Morgan's Insider Sales: A Planned Exit, Not a Red Flag, for a Resilient Midstream Giant

Kinder Morgan's Insider Sales: A Planned Exit, Not a Red Flag, for a Resilient Midstream Giant

12 hours ago

Top Headlines

View More →
Stock News•38 minutes ago

Rosen Law Firm Encourages Alibaba Group Holding Limited Investors to Inquire About Securities Class Action Investigation - BABA

Stock News•1 hour ago

Jimothy keeps on giving: Amazon and others match winning bid for raccoon art, to benefit food bank

Stock News•1 hour ago

Chipotle Mexican Grill (CMG) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Microsoft (MSFT) Ascends While Market Falls: Some Facts to Note

Stock News•1 hour ago

Securities Fraud Investigation Into Alphabet Inc. (GOOG) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz